CD8A and neoplasm: This suggests that the mRNA IT treatment could induce lower levels of cell surface MHC/peptide complexes compared to direct loading of MHC-I molecules by exogenously delivered minimal peptides, or that fewer tumor or non-tumor cells are transduced by the mRNA vaccine, thereby limiting antigen presentation to incoming CD8+ T cells and reducing local immune activation and cytotoxicity.